IRCT20220211053992N10招募中Unknown
Bioequivalence study of Apixaban 5 mg tablet manufactured by Sobhan Darou Co. compared with innovator product
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 59 years（—）
- 性别
- Male
入选标准
- •General Health (in terms of Liver, Heart and Kidney)
- •Age (18-59 years old)
排除标准
- •Alcohol and drug addiction
- •History of drug allergy
研究者
相似试验
已完成
不适用
Bioequivalence of ApixabaIRCT20210201050197N4Shahid Beheshti University of Medical Sciences24
已完成
不适用
Comparative in vivo evaluation of 2 ?Apixaban 5 mg Tablet formulations.IRCT20180620040164N37Actover Pharmaceutical Co.24
尚未招募
不适用
Comparative bioequivalence study of the Apixaban 5-mg Tablets manufactured by Darman Yab Darou Company-.IRCT20130313012810N10Darman Yab Darou Pharmaceutical Company24
已完成
1 期
A Bioequivalence Study of Two Formulations of Apixaban 5-mg Film-coated Tablets in Healthy Thai Subjects under Fasting ConditionsPrevention of venous thromboembolism (VTE) in adult patients who have undergone elective hip or knee replacement surgery, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), prevention of recurrent DVT and PE, prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF)Bioequivalence, Apixaban, PharmacokineticsTCTR20230109005T.O. Chemicals (1979) Ltd.26
尚未招募
1 期
A Bioequivalence Study of Two Formulations of Apixaban 5-mg Film-coated Tablets in Healthy Thai Subjects under Fasting ConditionsPrevention of venous thromboembolism in adult patients who have undergone elective hip or knee replacement surgery, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), prevention of recurrent DVT and PE, prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.Bioequivalence, apixaban, generic apixaban, pharmacokineticsTCTR20240811001SciGen Pte. Ltd.26